Authors: Savarese, DM Halabi, S Hars, V Akerley, WL Taplin, ME Godley, PA Hussain, A Small, EJ Vogelzang, NJ

Citation: Dm. Savarese et al., Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780, J CL ONCOL, 19(9), 2001, pp. 2509-2516

Authors: Burns, CP Halabi, S Clamon, GH Hars, V Wagner, BA Hohl, RJ Lester, E Kirshner, JJ Vinciguerra, V Paskett, E

Citation: Cp. Burns et al., Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B study 9473, CLIN CANC R, 5(12), 1999, pp. 3942-3947

Authors: Kantoff, PW Halabi, S Conaway, M Picus, J Kirshner, J Hars, V Trump, D Winer, EP Vogelzang, NJ

Citation: Pw. Kantoff et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractoryprostate cancer: Results of the Cancer and Leukemia Group B 9182 study, J CL ONCOL, 17(8), 1999, pp. 2506-2513

Authors: Demark-Wahnefried, W Hoben, KP Hars, V Jennings, J Miller, MW McClelland, JW

Citation: W. Demark-wahnefried et al., Utility of produce ratios to track fruit and vegetable consumption in a rural community, church-based 5 a day intervention project, NUTR CANCER, 33(2), 1999, pp. 213-217

Authors: Savarese, D Taplin, ME Halabi, S Hars, V Kreis, W Vogelzang, N

Citation: D. Savarese et al., A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780, SEMIN ONCOL, 26(5), 1999, pp. 39-44